Match!
Arun J. Sanyal
Virginia Commonwealth University
817Publications
102H-index
44.9kCitations
Publications 829
Newest
Abstract Background Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways involved in NASH. Design TANDEM (CLJC242A2201J; NCT03517540 ) is a 48-week, phase 2b, randomized, double-blind, multicenter study in 200 adult patients with b...
Source
#1Mohammad S. Siddiqui (VCU: Virginia Commonwealth University)H-Index: 15
#2Mark L. Van Natta (Johns Hopkins University)H-Index: 38
Last.Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 102
view all 12 authors...
Abstract Background Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). The present study evaluated the impact of OCA therapy on lipoprotein sub-particles. Method The study included 196 patients (99 OCA group and 97 placebo) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 w...
Source
Source
Source
Source
Abstract Background & Aims Increased levels of galectin 3 have been associated with nonalcoholic steatohepatitis (NASH) and contributes to toxin-induced liver fibrosis in mice. GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypertension in rats and was safe and well tolerated in phase 1 studies. We performed a phase 2b, randomized trial of the safety and efficacy of GR-MD-02 in patients with NASH, cirrhosis, and portal hypertension. Methods Patients wi...
Source
#1Somaya Albhaisi (VCU: Virginia Commonwealth University)H-Index: 1
#2Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 102
Nonalcoholic fatty liver disease (NAFLD) has now become a worldwide health issue due to the obesity epidemic, affecting approximately 90% of the obese population and 15–40% of the general population. It is the most common form of chronic liver disease in the United States. NAFLD constitutes a spectrum of diseases ranging in severity from mild, such as fatty liver, progressing into nonalcoholic steatohepatitis (NASH), then fibrosis, and ending with cirrhosis. NASH and increasing fibrosis stage ar...
Source
Summary Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease...
2 CitationsSource
#1Stephen A. HoangH-Index: 5
#2A. Oseini (VCU: Virginia Commonwealth University)H-Index: 3
Last.Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 102
view all 15 authors...
The heterogeneity of biological processes driving the severity of nonalcoholic fatty liver disease (NAFLD) as reflected in the transcriptome and the relationship between the pathways involved are not well established. Well-defined associations between gene expression profiles and disease progression would benefit efforts to develop novel therapies and to understand disease heterogeneity. We analyzed hepatic gene expression in controls and a cohort with the full histological spectrum of NAFLD. Pr...
Source
Abstract Background and Aim Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in patients with cirrhosis and portal pressure (assessed by the hepatic venous pressure gradient [HVPG]) ≥12 mmHg. We aimed to confirm these results in a randomized, placebo-controlled, double blind study. Methods Multicenter study including 263 patients with cirrhosis due to non-alcoholic steatohepatitis (NASH) and baseline HVPG ≥12 mmHg randomized 1:1:1:1 to emricasan 5...
Source
12345678910